Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. (Q50590836)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. |
scientific article |
Statements
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA (English)
Antonio Maria Risitano
Carmine Selleri
Bianca Serio
Giovanni Fernando Torelli
Sébastien Maury
Jörg Halter
Andrea Bacigalupo
Gerard Sociè
André Tichelli
Hubert Schrezenmeier
Judith Marsh
Bruno Rotoli
Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT)
7 December 2009